These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 8791009)
81. Characteristics of receptors for VIP in rat peritoneal macrophage membranes. Calvo JR; Guerrero JM; López-Gonzalez MA; Osuna C; Segura JJ Peptides; 1994; 15(2):309-15. PubMed ID: 8008637 [TBL] [Abstract][Full Text] [Related]
82. Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor. Langer I; Langlet C; Robberecht P J Mol Endocrinol; 2005 Apr; 34(2):405-14. PubMed ID: 15821106 [TBL] [Abstract][Full Text] [Related]
83. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies on opossum internal anal sphincter smooth muscle. Chakder S; Rattan S J Pharmacol Exp Ther; 1993 Jul; 266(1):392-9. PubMed ID: 8392560 [TBL] [Abstract][Full Text] [Related]
84. Pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP-receptor type 1 expression in rat and human placenta. Scaldaferri ML; Modesti A; Palumbo C; Ulisse S; Fabbri A; Piccione E; Frajese G; Moretti C Endocrinology; 2000 Mar; 141(3):1158-67. PubMed ID: 10698193 [TBL] [Abstract][Full Text] [Related]
85. Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals. Xia M; Sreedharan SP; Goetzl EJ J Clin Immunol; 1996 Jan; 16(1):21-30. PubMed ID: 8926282 [TBL] [Abstract][Full Text] [Related]
87. A chimeric VIP-PACAP analogue but not VIP pseudopeptides function as VIP receptor antagonists. Fishbein VA; Coy DH; Hocart SJ; Jiang NY; Mrozinski JE; Mantey SA; Jensen RT Peptides; 1994 Jan; 15(1):95-100. PubMed ID: 7912431 [TBL] [Abstract][Full Text] [Related]
88. Functional expression of VIP receptors in normal, immortalized and transformed mammary epithelial cells. Berthon P; Mirossay L; Ito S; Calvo F; Gespach C Life Sci; 1992; 50(11):791-8. PubMed ID: 1311049 [TBL] [Abstract][Full Text] [Related]
89. VIP receptors from porcine liver: high yield solubilization in a GTP-insensitive form. Voisin T; Couvineau A; Guijarro L; Laburthe M Life Sci; 1991; 48(2):135-41. PubMed ID: 1847224 [TBL] [Abstract][Full Text] [Related]
90. High affinity vasoactive intestinal peptide receptors on fetal human nonpigmented ciliary epithelial cells. Crook RB; Lui GM; Alvarado JA; Fauss DJ; Polansky JR Curr Eye Res; 1994 Apr; 13(4):271-9. PubMed ID: 8033589 [TBL] [Abstract][Full Text] [Related]
91. Diffuse pharmacophoric domains of vasoactive intestinal peptide (VIP) and further insights into the interaction of VIP with the N-terminal ectodomain of human VPAC1 receptor by photoaffinity labeling with [Bpa6]-VIP. Tan YV; Couvineau A; Laburthe M J Biol Chem; 2004 Sep; 279(37):38889-94. PubMed ID: 15247290 [TBL] [Abstract][Full Text] [Related]
92. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. el Battari A; Martin JM; Luis J; Pouzol O; Secchi J; Marvaldi J; Pichon J J Biol Chem; 1988 Nov; 263(33):17685-9. PubMed ID: 2846575 [TBL] [Abstract][Full Text] [Related]
93. Identification of cytoplasmic domains of hVPAC1 receptor required for activation of adenylyl cyclase. Crucial role of two charged amino acids strictly conserved in class II G protein-coupled receptors. Couvineau A; Lacapere JJ; Tan YV; Rouyer-Fessard C; Nicole P; Laburthe M J Biol Chem; 2003 Jul; 278(27):24759-66. PubMed ID: 12690118 [TBL] [Abstract][Full Text] [Related]
94. Structural and functional analysis of the human vasoactive intestinal peptide receptor glycosylation. Alteration of receptor function by wheat germ agglutinin. Chochola J; Fabre C; Bellan C; Luis J; Bourgerie S; Abadie B; Champion S; Marvaldi J; el Battari A J Biol Chem; 1993 Feb; 268(4):2312-8. PubMed ID: 8381403 [TBL] [Abstract][Full Text] [Related]
95. Characterization of functional receptors for vasoactive intestinal peptide in bovine cerebral arteries. Suzuki Y; McMaster D; Huang M; Lederis K; Rorstad OP J Neurochem; 1985 Sep; 45(3):890-9. PubMed ID: 2993516 [TBL] [Abstract][Full Text] [Related]
96. GI side-effects of a possible therapeutic GRF analogue in monkeys are likely due to VIP receptor agonist activity. Ito T; Igarashi H; Pradhan TK; Hou W; Mantey SA; Taylor JE; Murphy WA; Coy DH; Jensen RT Peptides; 2001 Jul; 22(7):1139-51. PubMed ID: 11445245 [TBL] [Abstract][Full Text] [Related]
97. Homologous regulation of vasoactive intestinal peptide (VIP) receptors on rat peritoneal macrophages. Pozo D; Guerrero JM; Calvo JR Peptides; 1995; 16(2):313-8. PubMed ID: 7784261 [TBL] [Abstract][Full Text] [Related]
98. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines. Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826 [TBL] [Abstract][Full Text] [Related]
99. VIP regulation of a human pancreatic cancer cell line: Capan-1. Ruellan C; Scemama JL; Clerc P; Fagot-Revurat P; Clemente F; Ribet A Peptides; 1986; 7 Suppl 1():267-71. PubMed ID: 3018700 [TBL] [Abstract][Full Text] [Related]
100. Characterization of VIP- and helodermin-preferring receptors on human small cell lung carcinoma cell lines. Luis J; Said SI Peptides; 1990; 11(6):1239-44. PubMed ID: 1965034 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]